Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : KalVista Pharmaceuticals
Deal Size : $22.0 million
Deal Type : Licensing Agreement
KalVista Licenses Sebetralstat to Kaken for HAE Market in Japan
Details : Under the licensing agreement, Kaken will holds the rights of KVD900 (sebetralstat) in Japan. It is being evaluated for the treatment of hereditary angioedema.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $11.0 million
April 08, 2025
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : KalVista Pharmaceuticals
Deal Size : $22.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Sirolimus Protein-bound Particle
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Whitehawk Therapeutics
Deal Size : $100.0 million
Deal Type : Divestment
Whitehawk Finalizes Aadi Sale To Kaken In Strategic Transformation
Details : Through the divestment, Kaken assumes ownership of FYARRO (sirolimus protein-bound particles for injectable suspension) used to treat adults with malignant perivascular epithelioid cell tumor.
Product Name : Fyarro
Product Type : Antibiotic
Upfront Cash : $100.0 million
March 26, 2025
Lead Product(s) : Sirolimus Protein-bound Particle
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Whitehawk Therapeutics
Deal Size : $100.0 million
Deal Type : Divestment
Lead Product(s) : ESK-001
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Alumis
Deal Size : $180.0 million
Deal Type : Collaboration
Alumis, Kaken Partner on ESK-001 for Dermatology in Japan
Details : The collaboration aims to develop, manufacture and commercialize ESK-001, a highly selective, next-gen oral TYK2 inhibitor, for dermatology indications in Japan.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $40.0 million
March 25, 2025
Lead Product(s) : ESK-001
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Alumis
Deal Size : $180.0 million
Deal Type : Collaboration
Lead Product(s) : KP-723
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Johnson & Johnson
Deal Size : $1,247.5 million
Deal Type : Licensing Agreement
Kaken, J&J Ink Potential $1.2B-Plus STAT6 Deal
Details : Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723, a preclinical STAT6 inhibitor, for autoimmune and allergic diseases, including atopic dermatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $30.0 million
December 26, 2024
Lead Product(s) : KP-723
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Johnson & Johnson
Deal Size : $1,247.5 million
Deal Type : Licensing Agreement
Lead Product(s) : ND081
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Recipient : Numab Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Numab and Kaken Collaborate On ND081 for Inflammatory Bowel Disease
Details : The collaboration aims to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD).
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : $14.6 million
November 15, 2024
Lead Product(s) : ND081
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Recipient : Numab Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Betahistine Dimesilate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Recipient : Eisai
Deal Size : $25.0 million
Deal Type : Divestment
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Details : Eisai divested its rights for Merislon (betahistine mesilate), used to treat Meniere's syndrome, and muscle relaxant Myonal (eperisone hydrochloride) in Japan to Kaken.
Product Name : Merislon
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 29, 2024
Lead Product(s) : Betahistine Dimesilate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Recipient : Eisai
Deal Size : $25.0 million
Deal Type : Divestment
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Recipient : CymaBay Therapeutics
Deal Size : $162.4 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market MBX-8025 (seladelpar), a first-in-class treatment for people with primary biliary cholangitis (PBC), in Japan for PBC.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $34.0 million
August 01, 2023
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Recipient : CymaBay Therapeutics
Deal Size : $162.4 million
Deal Type : Collaboration
Lead Product(s) : NM26-2198
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Numab Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
Details : NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : NM26-2198
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Numab Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tildacerfont
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : Spruce Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the HPA a...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
May 01, 2023
Lead Product(s) : Tildacerfont
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : Spruce Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Recipient : bitBiome
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, the companies will utilize the microbial platform technology developed by bitBiome to obtain drug candidates for the treatment of infectious diseases with high unmet medical needs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 29, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Recipient : bitBiome
Deal Size : Undisclosed
Deal Type : Agreement